During the past decade, Instituto de Investigaciones Metabolicas (Idim) conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 4 clinical trials were completed, i.e. on average, 26.7% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 4 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto de Investigaciones Metabolicas (Idim)" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "Merck Sharp & Dohme LLC" with 4 trials sponsored, "Shire" with 4 trials sponsored, "Amgen" with 1 trials sponsored and "Bio Sidus SA" with 1 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto de Investigaciones Metabolicas (Idim)" #1 collaborator was "Eisai Inc." with 2 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Instituto de Investigaciones Metabolicas (Idim)" are "Osteoporosis" (4 trials), "Prostatic Neoplasms" (2 trials), "Advanced Solid Tumor" (1 trials), "Advanced/Metastatic Gastroesophageal Adenocarcinoma" (1 trials) and "Biliary Tract Cancer" (1 trials). Many other conditions were trialed in "Instituto de Investigaciones Metabolicas (Idim)" in a lesser frequency.

Most popular intervention types in "Instituto de Investigaciones Metabolicas (Idim)" are "Drug" (20 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Pembrolizumab" (5 trials), "Cisplatin" (3 trials), "Lenvatinib" (3 trials) and "Paclitaxel" (3 trials). Other intervention names were less common.

The vast majority of trials in "Instituto de Investigaciones Metabolicas (Idim)" are 11 trials for "All" genders, 7 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto de Investigaciones Metabolicas (Idim)". undefined are not yet recruiting, 8 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Instituto de Investigaciones Metabolicas (Idim), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Instituto de Investigaciones Metabolicas (Idim), 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".

Instituto de Investigaciones Metabolicas (Idim) has several departments that took part in Clinical trials: "Consultorios Asociados de Endocrinología e Invest Clínica" - 2 trials